The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit - ATNM

Core Viewpoint - The Gross Law Firm is notifying shareholders of Actinium Pharmaceuticals, Inc. regarding a class action lawsuit due to alleged misleading statements related to the company's drug approval process [1][2]. Group 1: Allegations - The complaint alleges that during the class period from October 31, 2022, to August 2, 2024, the defendants made materially false and misleading statements regarding the Phase 3 Sierra trial data [2]. - It is claimed that the data from the Sierra trial was unlikely to meet FDA guidelines for the approval of the targeted radiotherapy, Iomab-B BLA [2]. - The additional analyses provided to the FDA to support the Sierra trial's poor overall survival data were also unlikely to satisfy FDA requirements [2]. - As a result of these issues, the FDA was expected to refuse to review the Iomab-B BLA or find it unlikely to approve the application in its current form [2]. - The defendants' positive statements about the company's business and prospects were deemed materially misleading and lacked a reasonable basis [2]. Group 2: Class Action Details - The deadline for shareholders to register for the class action is May 27, 2025, and they are encouraged to register promptly [3]. - Registered shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's progress [3]. - There is no cost or obligation for shareholders to participate in the case [3]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].